Citations 1
PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.
Galle, Peter R. , Luca, Angelo , Pelusio, Adina, Agathon, Delphine , Lusky, Monika, Breitbach, Caroline J. , Galle, Peter Robert , Abou‐Alfa, Ghassan K. , Chao, Yee , Brown, Karen T. , Heo, Jeong , Borad, Mitesh J. , Burke, James, Qin, Shukui
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS4146-TPS4146
